Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 51 to 60 of 176 total matches.

Jatenzo - An Oral Testosterone for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
cypionate – generic 1, 10 mL vials (100, 200 mg/mL)4,5 50-400 mg IM q2-4 weeks $74.90 Depo-Testosterone ...
An oral formulation of testosterone undecanoate (Jatenzo – Clarus) has been approved by the FDA for treatment of adult men with conditions associated with a deficiency of endogenous testosterone, such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Jatenzo is not approved for treatment of low testosterone levels solely due to aging. It is the first oral testosterone formulation to be approved in the US.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):103-4 |  Show IntroductionHide Introduction

Pitolisant (Wakix) for Narcolepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
Dosage Cost1 Armodafinil – generic C-IV 50, 150, 200, 250 mg tabs EDS: 150-250 mg once/day2 $65.90 ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):19-21 |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
, 100, 200 mg tabs 200-300 mg/day PO divided bid8 7.00 15, 25 mg caps 318.00 Topamax (Janssen) 25, 50 ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
/200, 90/400 mg tabs; 90/400 mg once/day x 12 weeks4 36,000.00 Harvoni (Gilead) 33.75/180, 45/200 mg ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
mL, 200 mg/2mL single-dose vials Dosage 350 mg x 1, then 700 mg at week 4, then 1,050 mg at week 8 ...
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2   doi:10.58347/tml.2024.1708e |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
Agent Ipratropium – Atrovent HFA 17 mcg/inh HFA MDI (200 inh/unit) 2 inh qid PRN $472.10 (Boehringer ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024  (Issue 1703)
(Valeant) 25 mg tabs 50-200 mg once/day or divided bid 291.60 1466.60 Furosemide – generic Lasix ...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8   doi:10.58347/tml.2024.1703a |  Show IntroductionHide Introduction

Encorafenib (Braftovi) for Metastatic Colorectal Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
prolongation has been reported with the drug. A 30-day supply of Braftovi costs $12,200. significantly longer ...
The FDA has approved the oral kinase inhibitor encorafenib (Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux), for treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. Encorafenib was approved in 2018 for use with the mitogen-activated kinase (MEK) inhibitor binimetinib (Mektovi) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):15-6 |  Show IntroductionHide Introduction

Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf. from 200 mg once daily to 300 mg and those ...
The Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca – Lilly) has received accelerated approval from the FDA for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a BTK inhibitor. Accelerated approval was based on the response rate. The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are also approved for treatment of MCL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e35-6   doi:10.58347/tml.2023.1670f |  Show IntroductionHide Introduction

Ribociclib (Kisqali) for Early Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
is supplied in 200-mg tablets. The recommended dosage for treatment of early breast cancer is 400 mg taken ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis), which was approved by the FDA in 2017 for use with an aromatase inhibitor or fulvestrant for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, has now been approved for use with an aromatase inhibitor for adjuvant treatment of HR-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence. Kisqali can be used in patients with node-positive or node-negative disease. The CDK 4/6...
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e202-3   doi:10.58347/tml.2024.1717f |  Show IntroductionHide Introduction